الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Macular edema due to retinal vein occlusion hold the second rank of the most common type of retinal vascular diseases after diabetic retinopathy.
Progressively blurry vision in patients with central retinal vein occlusion mainly results from macular edema ending with significant vision loss.
Most people with macular edema due to CRVO will need treatment and the number of options has increased in recent years.
Apart from panretinal photocoagulation for CRVO treatment, intravitreal corticosteroids have been used to treat macular edema secondary to CRVO but they are likely to increase the risk of cataract progression and intraocular pressure elevation.Recently, anti-vascular endothelial growth factor (VEGF) therapy has become the treatment of choice for this ocular disorder.
Ranibizumab and aflibercept have been licensed for treating various retinal diseases, while bevacizumab has been used off-label.
The current study was performed to review efficacy& safety of intravitreal aflibercept, ranibizumab and bevacizumab for the treatment of macular edema Secondary to central retinal vein occlusion.
This meta-analysis was conducted from 2010 to 2019. Literature search on PubMed, Cochrane library Ovid, Scopus & Google scholar was done to identify randomised controlled trials and comparative studies MedCalc ver. 18.2 (MedCalc, Ostend, Belgium) was used for data analysis.
Of the 14 articles included, there were 12 studies (out of 14 studies) were prospective RCTs; while 2 studies were retrospective studies. The meta-analysis was based on a total of 2650 eyes; 662 eyes in Aflibercept group, 406 eyes in Bevacizumab group, 430 eyes in Ranibizumab group, 1152 eyes in Control group.
Comparative study between Aflibercept group and Control group showed highly significant increase in mean BCVA in Aflibercept group compared to Control group (p < 0.001) and highly significant mean CRT decrease (p = 0.002).
It also showed non-significant difference in recurrence rate and complication rate in Aflibercept group compared to Control group (p > 0.05).
Comparative study between Bevacizumab group and Control group showed highly significant decrease in mean BCVA in Bevacizumab group compared to Control group (p = 0.005)and non-significant difference in mean CRT decrease (p > 0.05).
The meta-analysis study showed non-significant difference in complications rate in Bevacizumab group compared to Control group (p > 0.05).
Comparative study between Ranibizumab group and Control group showed non-significant difference in mean BCVA and mean CRT decrease in Ranibizumab group compared to Control group (p > 0.05).
The fixed-effects model of the meta-analysis study showed significant decrease in complications rate in Ranibizumab group compared to Control group (p = 0.025).